Silexion Therapeutics (SLXN) Total Current Liabilities (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Total Current Liabilities of $4.1 million for Q1 2026, up 69.52% year-over-year from $2.4 million in Q1 2025, and up 47.21% quarter-over-quarter from $2.8 million in Q4 2025.
Silexion Therapeutics (SLXN) Total Current Liabilities (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 69.52% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (up 69.52% YoY), while the FY2025 annual figure was $2.8 million, down 21.71% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $4.1 million, up from $2.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $4.1 million in Q1 2026, with the low at $2.2 million in Q2 2025.
- The 4-year median for Total Current Liabilities is $2.8 million (2025), against an average of $2.9 million.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities retreated 22.24% in 2025, then surged 69.52% in 2026.
- Silexion Therapeutics' Total Current Liabilities stood at $2.2 million in 2023, then jumped by 60.43% to $3.5 million in 2024, then fell by 21.71% to $2.8 million in 2025, then soared by 47.21% to $4.1 million in 2026.
- Business Quant data shows SLXN's Total Current Liabilities at $4.1 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Silexion Therapeutics | 267,449.04 | -1.96 Mn | - | 3.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.98 Mn |
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | 2.76 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 3.52 Mn |
| Sep 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Dec 31, 2023 | 2.20 Mn |